Granted Patent
B2
US 12,454,569 · App. 18/341,404 · Granted Oct 28, 2025
Method of reducing glucose intolerance or insulin resistance in a patient in need thereof
Assignee:
President and Fellows of Harvard College
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum.
Claims (14)
1. A method of reducing glucose intolerance in a human having glucose intolerance comprising administering to the human an effective amount of an Adipocyte Protein 2 (aP2)-specific antibody that specifically binds to aP2 in blood or serum.
2. The method of claim 1 , wherein administration of the aP2-specific antibody results in reduced blood glucose levels.
3. The method of claim 1 , wherein administration of the aP2-specific antibody results in reduced serum aP2 activity.
4. The method of claim 1 , wherein the aP2-specific antibody is a monoclonal antibody.
5. The method of claim 1 , wherein the aP2-specific antibody is a polyclonal antibody.
6. The method of claim 1 , wherein the human has a body mass index (BMI) of between 25 and 29.9.
7. The method of claim 1 , wherein the human has a BMI of greater than 30.
8. A method of reducing insulin resistance in a human having insulin resistance comprising administering to the human an effective amount of an Adipocyte Protein 2 (aP2)-specific antibody that specifically binds to aP2 in blood or serum.
9. The method of claim 8 , wherein administration of the aP2-specific antibody results in reduced blood glucose levels.
10. The method of claim 8 , wherein administration of the aP2-specific antibody results in reduced serum aP2 activity.
11. The method of claim 8 , wherein the aP2-specific antibody is a monoclonal antibody.
12. The method of claim 8 , wherein the aP2-specific antibody is a polyclonal antibody.
13. The method of claim 8 , wherein the human has a body mass index (BMI) of between 25 and 29.9.
14. The method of claim 8 , wherein the human has a BMI of greater than 30.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 19, 2025
From: HOTAMISLIGIL, GÖKHAN S.; CAO, HAIMING
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 070262/0468 →
Continuity (7)
Continuation
13203880
Provisional Application
61299170
· Jan 28, 2010
Provisional Application
61209251
· Mar 5, 2009
References Cited (83)
US 5858366A
· Sodroski et al.
· 1999
[cited by applicant]
US 5889167A
· Cascieri et al.
· 1999
[cited by applicant]
US 6548529B1
· Robl et al.
· 2003
[cited by applicant]
US 7390824B1
· Robl et al.
· 2008
[cited by applicant]
US 8846413B2
· Ruzicka
· 2014
[cited by applicant]
US 9879078B2
· Hotamisligil et al.
· 2018
[cited by applicant]
US 20020035064A1
· Robl et al.
· 2002
[cited by applicant]
US 20040010119A1
· Guo et al.
· 2004
[cited by applicant]
US 20050147588A1
· Liu et al.
· 2005
[cited by applicant]
US 20120134998A1
· Hotamisligil et al.
· 2012
[cited by applicant]
US 20150093769A1
· Ruzicka
· 2015
[cited by applicant]
US 20230203142A1
· Hotamisligil et al.
· 2023
[cited by applicant]
DE 102006034607A1
· 2007
[cited by applicant]
WO WO200015229A1
· 2000
[cited by applicant]
WO WO200015230A1
· 2000
[cited by applicant]
WO WO200047734A1
· 2000
[cited by applicant]
WO WO2003043624A1
· 2003
[cited by applicant]
WO WO2010057260A1
· 2010
[cited by applicant]
Banaszak et al. Lipid-binding proteins: a family of fatty acid and retinoid transport proteins. Adv. Protein Chem. 45:89-151(1994).
[cited by applicant]
Barf et al. N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors. Bioorganic and Medicinal Chemistry Letters. 19(6):1745-1748(Mar. 15, 2…
[cited by applicant]
Baxa et al. Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry. 28:8683-8690(1989).
[cited by applicant]
Blanc et al. Exosome release by reticulocytes—An integral part of the red blood cell differentiation system. Blood Cells, Molecules and Diseases. 35:21-26(2005).
[cited by applicant]
Boord et al. Adipocyte Fatty Acid-Binding protein, aP2, Alters Late Atherosclerotic Lesion Formation in Severe Hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 22(10):1686-1691(Oct. 2002).
[cited by applicant]
Brand, C.L. et al. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycemia in moderately streptozotocin-diabetic rats. Diabetologia. 37(10):985-993(1994).
[cited by applicant]
Braun, D.A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine. 26:909-918(2020).
[cited by applicant]
Burak Furkan, M.D. et al. M development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. Sci Trans Med. 7(3):1-17(2015).
[cited by applicant]
Cabre et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis. 195(1):e150-e158(Nov. 2007).
[cited by applicant]
Cao et al. Regulation of Metabolic Responses by Adipocyte/Macrophage Fatty Acid-Binding Proteins in Leptin-Deficient Mice. Diabetes. 55:1915-1922(Jul. 2006).
[cited by applicant]
Cao et al. Identification of a Lipokine, a Lipid Hormone Linking Adipose Tissue to Systemic Metabolism. Cell. 134:933-944(Sep. 19, 2008).
[cited by applicant]
Cao et al. Adipocyte lipid chaperone aP2 is a secreted adipokine regulating hepatic glucose production. Cell Metabolism. 17(5):768-778(May 2013).
[cited by applicant]
Cayman Chemical FABP4 Polyclonal Antibody product sheet (5 pages) downloaded on Sep. 30, 2015.
[cited by applicant]
Chamov & Ashkanazi. Tibtech 14:52-60(1996).
[cited by applicant]
Distel et al. Fatty Acid Regulation of Gene Expression: Transcriptional and Post-Transcriptional Mechanism. The Journal of Biological Chemistry. 267(9):5937-5941(Mar. 25, 1992).
[cited by applicant]
Erbay et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nature Medicine. 15(12):1383-1391(Dec. 2009).
[cited by applicant]
Fu et al. Oxidized LDL induces the expression of ALBP/aP2 mRNA and protein in human THP-1 macrophages. Journal of Lipid Research. 41(12): 2017-2023(Dec. 2000).
[cited by applicant]
Furuhashi et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 447(21):959-965(2007).
[cited by applicant]
Furuhashi et al. Adipocyte/Macrophage Fatty Acid-Binding Proteins Contribute to Metabolic Deterioration Through Actions in Both Macrophages and Adipocytes in Mice. J Clin Invest. 118(7):2640-2650(Jul. 2008).
[cited by applicant]
Gillilan et al. Structural Basis for Activation of Fatty Acid-binding Protein 4. J Mol Biol. 372:1246-1260(2007).
[cited by applicant]
Girona et al. FABP4 Induces Vascular Smooth Muscle Cell Proliferation and Migration through a MAPK-Dependent Pathway. PLoS One. 8(11):e81914(Nov. 2013).
[cited by applicant]
Gorbenko et al. Generation and Characterization of Monoclonal Antibodies against FABP4. Hybridoma. 25(2):86-90(2006).
[cited by applicant]
Hecker et al. Heat Shock proteins as biomarkers for the rapid detection of brain and spinal cord ischemia: a review and comparison to other methods of detection in thoracic aneurysm repair. Cell Stress and Chaperones. 1…
[cited by applicant]
Hellberg et al. X-ray crystallographic analysis of adipocyte fatty acid binding protein (aP2) modified with 4-hydroxy-2-nonenal. Protein Science. 19:1480-1489(2010).
[cited by applicant]
Hertzel et al. The Mammalian Fatty Acid-binding Protein Multigene Family: Molecular and Genetic Insights into Function. Trends in Endocrinology & Metabolism. 11(5):175-180(2000).
[cited by applicant]
Hertzel et al. Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins. Journal of Medicinal Chemistry, 52(19):6024-6031(Oct. 8, 2009).
[cited by applicant]
Hotamisligil et al. Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in aP2, the Adipocyte Fatty Acid Binding Protein. Science. 274(5291):1377-1379(Nov. 22, 1996).
[cited by applicant]
Hunt et al. Adipocyte P2 gene: Developmental expression and homology of 5′-flanking sequences among fat cell-specific genes. PNAS. 83:3786-3790(Jun. 1986).
[cited by applicant]
Hunter-Lavin et al. Hsp70 release from peripheral blood mononuclear cells. Biochemical and Biophysical Research Communications. 324(2):511-517(Nov. 12, 2004).
[cited by applicant]
International Search Report for PCT/US2010/026305 mailed Oct. 4, 2010.
[cited by applicant]
Joyner CJ et al., Development of a monoclonal antibody to the aP2 protein to identify adipocyte precursors in tumours of adipose differentiation. Pathology Research and Practice. 195(7):461-466(1999).
[cited by applicant]
Kajimura et al. Regulation of the brown and white fat gene programs through a PRDM16/ctBp transcriptional complex. Genes & Development. 22:1397-1409(2008).
[cited by applicant]
Karakas et al. Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. Metabolism Clinical and Experimental. 58:1002-1007(2009).
[cited by applicant]
Lalonde et al. X-ray Crystallographic Structures of Adipocyte Lipid-Binding Protein Complexed with Palmitate and Hexadecanesulfonic Acid. Properties of Cavity Binding Sites. Biochemistry. 33:4885-4895(1994).
[cited by applicant]
Lan et al. Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with diet-induced obesity. Journal of Lipid Research. 52(4):646-656(Apr. 2011).
[cited by applicant]
Layne et al. Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice. The FASEB Journal. 15:2733-2735(Dec. 2001).
[cited by applicant]
Lehman et al. Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorganic and Medicinal Chemistry Letters. 14(17):4445-4448(Sep. 6, 2004).
[cited by applicant]
Maeda et al. Adipocyte/Macrophage Fatty-Acid Bonding Proteins Control Integrated Metabolic Responses in Obesity and Diabetes. Cell Metab. 1:107-119(Feb. 2005).
[cited by applicant]
Makowski et al. Lack of Macrophage Fatty-Acid-Binding Protein aP2 Protects Mice Deficient in Apolipoprotein E Against Atherosclerosis. Nat. Med. 7(6):699-705(Jun. 2001).
[cited by applicant]
Makowski et al. The Fatty Acid-binding Protein, aP2, Coordinates Macrophage Cholesterol Trafficking and Inflammatory Activity. The Journal of Biological Chemistry. 280(13):12888-12895(Apr. 1, 2005).
[cited by applicant]
Melki et al. Expression of the adipocyte fatty acid-binding protein streptozotocin-diabetes: effects of insulin deficiency and supplementation. Journal of Lipid Research. 34:1527-1534(1993).
[cited by applicant]
Ozcan et al. Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes. Science. 313(5790):1137-1140(Aug. 25, 2006).
[cited by applicant]
PCT/US2016/030303, Invitation to pay additional fees and, where applicable, protest fee, mailed Sep. 12, 2016.
[cited by applicant]
Ringom et al. Substituted benzylamino-6-(trufluoromethyl)pyramidin-4(1 H)-ones: a novel class of selective human FABP inhibitors. Bioorganic and Medicinal Chemistry Letters. 14:4449-4452(2004).
[cited by applicant]
Rosen et al. Adipocytes as Regulators of Energy Balance and Glucose Homeostasis. Nature. 444:847-853(Dec. 14, 2006).
[cited by applicant]
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci. 79(6):1979-1983(1982).
[cited by applicant]
Storch et al. Structural and functional analysis of fatty acid-binding proteins. Journal of Lipid Research. 50:S126-S131(2009).
[cited by applicant]
Sulsky et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorganic and Medicinal Chemistry Letters. 17(12):351-3515(Jun. 15, 2007).
[cited by applicant]
Tuncman et al. A genetic variant at the fattyacid-binding protein aP2 locus reduces the risk for hypertriglceridemia, type 2 diabetes, and cardiovascular disease. PNAS. 103(18):6970-6975(May 2, 2006).
[cited by applicant]
Uysal et al. Improved Glucose and Lipid Metabolism in Genetically Obese Mice Lacking aP2. Endocrinology. 141:3388-3396(2000).
[cited by applicant]
Van Dongen et al. Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation. Journal of the American Chemical Society. 124(40):11874-11880(Oct. 9, 2002).
[cited by applicant]
Vernochet et al. C/EBPalpha and the Corepressors CtBP2 Regulate Repression of Select Visceral White Adipose Genes during Induction of the Brown Phenotype in White Adipocytes by Peroxisome Proliferator-Activated Receptor…
[cited by applicant]
Written Opinion of the International Search Authority for PCT/US2010/026305 mailed on Sep. 5, 2011.
[cited by applicant]
Xu et al. The adipocyte lipid-binding protein at 1.6-A resolution. Crystal structures of the apoprotein and with bound saturated and unsaturated fatty acids. Journal of Biological Chemistry. 268:7874-7884(1993).
[cited by applicant]
Xu et al. Adipocyte Fatty-Acid-Binding Protein is a Plasma Biomarker Closely Associated with Obesity and Metabolic Syndrome. Clinical Chemistry. 52(3):405-413(2006).
[cited by applicant]
Xu et al. Circulating Adipocyte-Fatty Acid Binding Protein Levels Predict the Development of the Metabolic Syndrome—A 5-year Prospective Study. Circulation. 115:1537-1543(2007).
[cited by applicant]
Zhang et al. Exosomes a novel pathway to local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. American Journal of Pathology. 184(1):28-41(Jan. 2014).
[cited by applicant]